網頁2024年10月6日 · The Department of Health and Human Services (HHS) says it has spent $290 million on a drug to treat radiation sickness in the event of a nuclear emergency. … 網頁2024年2月25日 · Diagnosis. To diagnose immune thrombocytopenia, your doctor will try to exclude other possible causes of bleeding and a low platelet count, such as an underlying illness or medications you or your child may be taking. Blood tests can check the levels of platelets. Rarely, adults might need a bone marrow exam to rule out other problems.
Karim Elshabrawi - MEA Medical Science Liaison - Stemline …
網頁Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful. However, Nplate is administered … 網頁2024年10月7日 · Nplate, manufactured by U.S. drugmaker Amgen, was approved by the Food and Drug Administration in 2024 to treat injuries caused by acute radiation … refresh optive tears ingredients
Nplate (romiplostim) dosing, indications, interactions, adverse …
網頁Other names: Immune Thrombocytopenic Purpura; ITP. Idiopathic Thrombocytopenic Purpura is a systemic illness characterized by ecchymoses (extensive purplish patchs caused by extravasation of blood into the skin) and hemorrhages from mucous membranes and very low platelet counts. It results from platelet destruction by macrophages due to … 網頁Patient centric, optimistic, Highly resilient, enthusiastic, self-motivated, task oriented and problem solver with 13 years’+ experience in multinational pharmaceutical companies within Egypt, Lebanon, Libya, Saudi Arabia, Oman, Kuwait, Qatar and UAE in multiple disease areas including Oncology (Breast Cancer, ColoRectal Cancer), Hematology (Leukemia), … 網頁2024年10月6日 · The United States is stockpiling medications for radiation sickness, which might be a worrying sign of the times. On Wednesday, the US Department of Health and Human Services (HHS) announced that it would spend $290 million to secure an undisclosed quantity of Amgen's blood disorder drug Nplate, which has been approved … refresh optive vs plus